Navigation Links
First diagnostic test for Alzheimer's and Parkinson's disease on the horizon
Date:4/6/2008

A new blood test that can give an early diagnosis of neurodegenerative disease and distinguish between Parkinsons and Alzheimers disease could be launched this summer, reports Marina Murphy in SCIs Chemistry & Industry magazine.

Manufacturer, Oklahoma-based proteomics company, Power3 Medical Products, said it plans to sell the test, NuroPro, which would be the first diagnostic test for neurodegenerative diseases on the market, in Greece by Q3 with further plans for it to go on the US market by late Q3 or Q4.

There is currently no diagnostic test for any neurodegenerative disease on the market diagnoses are currently based solely on a clinical diagnosis of symptoms, said chief executive, Steve Rash.

Power3 has identified and patented several blood proteins(1) associated with neurodegenerative disease. The test NuroPro measures a suite of 59 protein biomarkers, the relative levels of which, they say, can help distinguish between Parkinsons, Alzheimers and Lou Gehrigs disease or tell whether a patient is disease free. The test is highly accurate with a specificity and sensitivity in the high 90s, according to Rash.

Although the test has been welcomed by Kieran Breen, director of research at the Parkinsons Disease Society, as being particularly useful for monitoring the progression of disease and assessing the effectiveness of drugs, he urged caution saying: While the test seems promising, larger studies need to be conducted before it can be confirmed as being helpful in making a diagnosis.

Susan Sorensen, head of research at the UK Alzheimers Society said: There are 700,000 people living with dementia in the UK, 62 per cent have Alzheimers disease and this will rise to more than a million in less than 20 years. An effective blood test would present those diagnosed and their families with an opportunity to prepare for the impact of this devastating illness and make crucial decisions about their future.

The method, known as proteomics, involves analysing proteins in the blood although it remains unclear which group of proteins gives the definitive signs of Alzheimers disease Some suggest Alzheimers, for example, is too complex to be identified in this way.

Two clinical validation studies are currently underway at the Cleo Roberts Center of Clinical Research in Arizona, US, and the Research Institute of Thessaly in Greece.


'/>"/>

Contact: Meral Nugent
meral.nugent@soci.org
44-020-759-81533
Society of Chemical Industry
Source:Eurekalert

Related biology news :

1. Which came first, the moth or the cactus?
2. First all-African GM crop is resistant to maize streak virus
3. Scientists retrace evolution with first atomic structure of an ancient protein
4. CU-Boulder team discovers first ancient manioc fields in Americas
5. First finding of a metabolite in 1 sex only
6. First orchid fossil puts showy blooms at some 80 million years old
7. First individual genome sequence published
8. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
9. UNH becomes first university in nation to use landfill gas as primary energy source
10. Scientists in first global study of poison gas in the atmosphere
11. Weight gain between first and second pregnancies associated with increased odds of male second child
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... June 22, 2016  Mesa Biotech Inc., a ... testing platform designed specifically for point-of-care (POC) infectious ... scientific advisory board (SAB). Approved by the executive ... is chartered to advise on the development and ... Led by Dr. Steve Young , this ...
Breaking Biology Technology: